Amy Shah
Concepts (368)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 2 | 66 | 2026 | 2588 | 9.660 |
Why?
| | Vascular Stiffness | 23 | 2025 | 486 | 6.350 |
Why?
| | Diabetes Mellitus, Type 1 | 45 | 2026 | 3922 | 4.260 |
Why?
| | Lipoproteins, HDL | 11 | 2025 | 100 | 3.400 |
Why?
| | Cardiovascular Diseases | 27 | 2025 | 2187 | 3.320 |
Why?
| | Pediatric Obesity | 13 | 2026 | 638 | 2.760 |
Why?
| | Adolescent | 100 | 2026 | 22529 | 2.390 |
Why?
| | Diabetic Angiopathies | 9 | 2025 | 264 | 2.180 |
Why?
| | Dyslipidemias | 10 | 2026 | 184 | 2.140 |
Why?
| | Bariatric Surgery | 6 | 2026 | 252 | 2.000 |
Why?
| | Apolipoprotein A-I | 9 | 2025 | 39 | 1.990 |
Why?
| | Pulse Wave Analysis | 20 | 2025 | 267 | 1.950 |
Why?
| | Gastrectomy | 4 | 2026 | 166 | 1.810 |
Why?
| | Lipoproteins, LDL | 5 | 2025 | 119 | 1.680 |
Why?
| | Body Mass Index | 19 | 2026 | 2445 | 1.630 |
Why?
| | Carotid Intima-Media Thickness | 7 | 2020 | 75 | 1.590 |
Why?
| | Obesity, Morbid | 5 | 2024 | 293 | 1.560 |
Why?
| | Young Adult | 56 | 2026 | 14218 | 1.520 |
Why?
| | Lipoproteins | 6 | 2021 | 166 | 1.510 |
Why?
| | Obesity | 21 | 2026 | 3116 | 1.500 |
Why?
| | Child | 70 | 2026 | 22707 | 1.490 |
Why?
| | Blood Glucose | 13 | 2026 | 2341 | 1.400 |
Why?
| | Endocrinology | 2 | 2024 | 77 | 1.360 |
Why?
| | Hypoglycemic Agents | 8 | 2026 | 1399 | 1.290 |
Why?
| | Gray Matter | 3 | 2025 | 92 | 1.260 |
Why?
| | Age of Onset | 12 | 2026 | 555 | 1.220 |
Why?
| | Risk Factors | 39 | 2024 | 10885 | 1.170 |
Why?
| | Humans | 133 | 2026 | 145474 | 1.160 |
Why?
| | Carotid Arteries | 7 | 2020 | 208 | 1.160 |
Why?
| | Cholesterol | 7 | 2024 | 408 | 1.080 |
Why?
| | Proteoglycans | 2 | 2025 | 112 | 1.060 |
Why?
| | Male | 85 | 2026 | 72842 | 1.000 |
Why?
| | Cross-Sectional Studies | 21 | 2025 | 5904 | 0.970 |
Why?
| | Female | 84 | 2026 | 78844 | 0.960 |
Why?
| | Diabetes Mellitus | 5 | 2026 | 1097 | 0.950 |
Why?
| | Atherosclerosis | 3 | 2024 | 409 | 0.930 |
Why?
| | Delayed Diagnosis | 1 | 2025 | 100 | 0.870 |
Why?
| | Heart Rate | 6 | 2022 | 855 | 0.850 |
Why?
| | Lipids | 8 | 2022 | 707 | 0.840 |
Why?
| | Gastroparesis | 1 | 2022 | 9 | 0.760 |
Why?
| | Weight Loss | 4 | 2026 | 858 | 0.760 |
Why?
| | Prediabetic State | 2 | 2016 | 249 | 0.690 |
Why?
| | Metabolic Syndrome | 1 | 2025 | 360 | 0.690 |
Why?
| | Adult | 36 | 2026 | 40777 | 0.680 |
Why?
| | Triglycerides | 7 | 2025 | 520 | 0.670 |
Why?
| | Apolipoproteins B | 2 | 2024 | 47 | 0.670 |
Why?
| | Hypertriglyceridemia | 3 | 2021 | 45 | 0.650 |
Why?
| | Hypertrophy, Left Ventricular | 1 | 2021 | 124 | 0.640 |
Why?
| | Echocardiography | 2 | 2021 | 647 | 0.630 |
Why?
| | Autonomic Nervous System Diseases | 2 | 2019 | 37 | 0.630 |
Why?
| | Nervous System Diseases | 1 | 2023 | 286 | 0.610 |
Why?
| | Gastric Bypass | 1 | 2021 | 126 | 0.600 |
Why?
| | Insulin Resistance | 7 | 2026 | 1244 | 0.590 |
Why?
| | Cholesterol, HDL | 6 | 2021 | 201 | 0.590 |
Why?
| | Ventricular Remodeling | 1 | 2021 | 278 | 0.580 |
Why?
| | Proteome | 4 | 2021 | 514 | 0.560 |
Why?
| | Prevalence | 10 | 2025 | 2865 | 0.560 |
Why?
| | Apolipoprotein A-II | 4 | 2024 | 5 | 0.550 |
Why?
| | Cardiomyopathies | 1 | 2022 | 335 | 0.540 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2021 | 394 | 0.530 |
Why?
| | Ventricular Function, Left | 1 | 2021 | 542 | 0.530 |
Why?
| | Disease Progression | 6 | 2022 | 2864 | 0.520 |
Why?
| | Hypertension | 7 | 2025 | 1273 | 0.510 |
Why?
| | White Matter | 1 | 2019 | 153 | 0.490 |
Why?
| | Atrial Fibrillation | 1 | 2023 | 558 | 0.490 |
Why?
| | Arrhythmias, Cardiac | 1 | 2019 | 355 | 0.490 |
Why?
| | Cholesterol, LDL | 5 | 2024 | 360 | 0.480 |
Why?
| | Chemical Precipitation | 1 | 2016 | 39 | 0.470 |
Why?
| | Ohio | 5 | 2016 | 146 | 0.470 |
Why?
| | Metabolic Diseases | 1 | 2017 | 114 | 0.470 |
Why?
| | Executive Function | 2 | 2019 | 470 | 0.430 |
Why?
| | Cognitive Dysfunction | 3 | 2023 | 467 | 0.430 |
Why?
| | Cohort Studies | 13 | 2025 | 6013 | 0.430 |
Why?
| | Pediatrics | 2 | 2020 | 1121 | 0.430 |
Why?
| | Problem Behavior | 1 | 2016 | 101 | 0.430 |
Why?
| | Quinolines | 2 | 2026 | 190 | 0.420 |
Why?
| | Arteries | 1 | 2016 | 261 | 0.410 |
Why?
| | Phosphatidylcholine-Sterol O-Acyltransferase | 3 | 2025 | 8 | 0.410 |
Why?
| | Biomarkers | 9 | 2026 | 4295 | 0.400 |
Why?
| | Vasculitis | 1 | 2014 | 69 | 0.400 |
Why?
| | Vasodilation | 1 | 2017 | 521 | 0.400 |
Why?
| | Peripheral Vascular Diseases | 1 | 2014 | 104 | 0.400 |
Why?
| | Case-Control Studies | 8 | 2021 | 3623 | 0.400 |
Why?
| | Microvessels | 1 | 2014 | 97 | 0.380 |
Why?
| | Adiposity | 2 | 2015 | 532 | 0.380 |
Why?
| | Vitamin D Deficiency | 1 | 2015 | 190 | 0.380 |
Why?
| | Albuminuria | 3 | 2025 | 189 | 0.380 |
Why?
| | Follow-Up Studies | 10 | 2026 | 5423 | 0.370 |
Why?
| | Vascular Resistance | 1 | 2014 | 370 | 0.370 |
Why?
| | Sphygmomanometers | 1 | 2012 | 7 | 0.360 |
Why?
| | Pancreatitis | 3 | 2026 | 146 | 0.360 |
Why?
| | Pilot Projects | 5 | 2025 | 1891 | 0.360 |
Why?
| | Mercury | 1 | 2012 | 41 | 0.350 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2026 | 443 | 0.350 |
Why?
| | Vitamin D | 1 | 2015 | 403 | 0.350 |
Why?
| | Endothelium, Vascular | 2 | 2017 | 956 | 0.340 |
Why?
| | Age Factors | 8 | 2020 | 3342 | 0.340 |
Why?
| | Diastole | 2 | 2022 | 146 | 0.340 |
Why?
| | Blood Pressure Determination | 1 | 2012 | 145 | 0.340 |
Why?
| | Cerebrovascular Circulation | 2 | 2025 | 289 | 0.330 |
Why?
| | Adolescent Behavior | 1 | 2016 | 494 | 0.330 |
Why?
| | Carotid Artery, Internal | 1 | 2011 | 45 | 0.330 |
Why?
| | Feeding Behavior | 3 | 2025 | 690 | 0.320 |
Why?
| | C-Peptide | 3 | 2026 | 190 | 0.310 |
Why?
| | Insulin | 5 | 2026 | 2512 | 0.310 |
Why?
| | Treatment Outcome | 6 | 2026 | 11772 | 0.310 |
Why?
| | Protein Binding | 3 | 2025 | 2238 | 0.310 |
Why?
| | Adiponectin | 1 | 2012 | 241 | 0.310 |
Why?
| | Early Diagnosis | 2 | 2025 | 251 | 0.310 |
Why?
| | Genetic Predisposition to Disease | 4 | 2021 | 2378 | 0.300 |
Why?
| | Lipid Metabolism | 1 | 2013 | 529 | 0.290 |
Why?
| | Blood Pressure | 6 | 2015 | 1779 | 0.290 |
Why?
| | Particle Size | 4 | 2021 | 381 | 0.290 |
Why?
| | Proprotein Convertase 9 | 2 | 2020 | 87 | 0.280 |
Why?
| | Incidence | 5 | 2024 | 2923 | 0.280 |
Why?
| | Heart Failure | 1 | 2022 | 2326 | 0.270 |
Why?
| | Prospective Studies | 6 | 2024 | 8057 | 0.260 |
Why?
| | Heart | 2 | 2023 | 626 | 0.260 |
Why?
| | Mass Spectrometry | 6 | 2019 | 730 | 0.260 |
Why?
| | Smoking | 1 | 2014 | 1472 | 0.250 |
Why?
| | Pancreas, Exocrine | 1 | 2026 | 7 | 0.240 |
Why?
| | Overweight | 2 | 2026 | 614 | 0.240 |
Why?
| | Exocrine Pancreatic Insufficiency | 1 | 2026 | 24 | 0.230 |
Why?
| | Apolipoprotein A-V | 1 | 2025 | 4 | 0.230 |
Why?
| | Lipoproteins, VLDL | 1 | 2025 | 21 | 0.230 |
Why?
| | Retrospective Studies | 10 | 2026 | 17291 | 0.230 |
Why?
| | ATP Binding Cassette Transporter 1 | 3 | 2024 | 13 | 0.230 |
Why?
| | Biological Transport | 4 | 2024 | 424 | 0.220 |
Why?
| | Apolipoproteins E | 1 | 2025 | 93 | 0.220 |
Why?
| | Brain | 3 | 2025 | 2947 | 0.220 |
Why?
| | Food Assistance | 1 | 2025 | 29 | 0.220 |
Why?
| | Pancreatitis, Chronic | 1 | 2025 | 64 | 0.210 |
Why?
| | Magnetic Resonance Imaging | 4 | 2025 | 3904 | 0.210 |
Why?
| | Dietary Carbohydrates | 1 | 2025 | 147 | 0.210 |
Why?
| | Multiple Endocrine Neoplasia Type 1 | 1 | 2024 | 2 | 0.210 |
Why?
| | Insulinoma | 1 | 2024 | 29 | 0.210 |
Why?
| | Pregnancy in Diabetics | 1 | 2026 | 123 | 0.210 |
Why?
| | Risk Assessment | 4 | 2021 | 3747 | 0.200 |
Why?
| | Preoperative Period | 1 | 2024 | 149 | 0.200 |
Why?
| | United States | 11 | 2026 | 16098 | 0.190 |
Why?
| | Insulin Glargine | 1 | 2023 | 88 | 0.190 |
Why?
| | Longitudinal Studies | 5 | 2023 | 2953 | 0.190 |
Why?
| | Extracellular Vesicles | 1 | 2025 | 171 | 0.190 |
Why?
| | Pharmacy | 1 | 2023 | 32 | 0.190 |
Why?
| | Mice | 7 | 2025 | 18329 | 0.180 |
Why?
| | Sex Factors | 3 | 2015 | 2105 | 0.180 |
Why?
| | Pandemics | 4 | 2026 | 1707 | 0.180 |
Why?
| | Mass Screening | 3 | 2022 | 1360 | 0.180 |
Why?
| | Proteomics | 4 | 2021 | 1188 | 0.180 |
Why?
| | Diabetic Neuropathies | 2 | 2023 | 100 | 0.180 |
Why?
| | Lipid Metabolism Disorders | 1 | 2021 | 4 | 0.180 |
Why?
| | Off-Label Use | 1 | 2022 | 51 | 0.180 |
Why?
| | Diabetic Nephropathies | 3 | 2020 | 322 | 0.170 |
Why?
| | Meta-Analysis as Topic | 1 | 2022 | 171 | 0.170 |
Why?
| | Receptors, CXCR3 | 1 | 2021 | 17 | 0.170 |
Why?
| | Pyruvate Kinase | 1 | 2021 | 28 | 0.170 |
Why?
| | Radiation Oncology | 1 | 2022 | 82 | 0.170 |
Why?
| | Sleep Apnea, Obstructive | 1 | 2025 | 302 | 0.170 |
Why?
| | Thyroid Hormones | 1 | 2021 | 68 | 0.160 |
Why?
| | Autoantibodies | 2 | 2025 | 1509 | 0.160 |
Why?
| | Lipoprotein(a) | 1 | 2021 | 69 | 0.160 |
Why?
| | Quantitative Trait, Heritable | 1 | 2021 | 113 | 0.160 |
Why?
| | Insulin-Secreting Cells | 1 | 2025 | 392 | 0.160 |
Why?
| | Regression Analysis | 2 | 2014 | 1001 | 0.160 |
Why?
| | Animals | 9 | 2025 | 38030 | 0.160 |
Why?
| | Cognition | 3 | 2023 | 1266 | 0.160 |
Why?
| | Th17 Cells | 1 | 2021 | 101 | 0.160 |
Why?
| | Chromosome Mapping | 1 | 2021 | 506 | 0.160 |
Why?
| | Drug Chronotherapy | 1 | 2019 | 2 | 0.150 |
Why?
| | Turner Syndrome | 1 | 2020 | 65 | 0.150 |
Why?
| | Diabetic Ketoacidosis | 1 | 2022 | 209 | 0.150 |
Why?
| | Radiology | 1 | 2022 | 174 | 0.150 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2026 | 652 | 0.150 |
Why?
| | Cell Adhesion Molecules | 1 | 2020 | 181 | 0.150 |
Why?
| | Research | 1 | 2022 | 430 | 0.150 |
Why?
| | Autonomic Nervous System | 1 | 2019 | 82 | 0.140 |
Why?
| | Neurology | 1 | 2020 | 116 | 0.140 |
Why?
| | Kidney Diseases | 1 | 2023 | 425 | 0.140 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2025 | 1747 | 0.140 |
Why?
| | Islets of Langerhans | 1 | 2025 | 846 | 0.140 |
Why?
| | Oxidation-Reduction | 3 | 2018 | 1067 | 0.140 |
Why?
| | Stroke Volume | 1 | 2022 | 654 | 0.140 |
Why?
| | Multivariate Analysis | 3 | 2017 | 1547 | 0.140 |
Why?
| | Hypolipidemic Agents | 1 | 2019 | 89 | 0.140 |
Why?
| | Shock, Septic | 1 | 2020 | 227 | 0.140 |
Why?
| | Alleles | 1 | 2021 | 894 | 0.140 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2021 | 265 | 0.130 |
Why?
| | Weight Reduction Programs | 1 | 2019 | 140 | 0.130 |
Why?
| | Blood Chemical Analysis | 1 | 2018 | 109 | 0.130 |
Why?
| | Anticonvulsants | 1 | 2020 | 246 | 0.130 |
Why?
| | Predictive Value of Tests | 2 | 2021 | 2121 | 0.130 |
Why?
| | Vascular Diseases | 1 | 2020 | 252 | 0.130 |
Why?
| | Physicians, Primary Care | 1 | 2020 | 208 | 0.130 |
Why?
| | Dwarfism, Pituitary | 1 | 2017 | 2 | 0.130 |
Why?
| | Pharmaceutical Preparations | 1 | 2019 | 170 | 0.130 |
Why?
| | Drug Administration Schedule | 1 | 2019 | 782 | 0.130 |
Why?
| | Phenotype | 2 | 2026 | 3155 | 0.130 |
Why?
| | Prognosis | 5 | 2026 | 4316 | 0.130 |
Why?
| | Linear Models | 4 | 2015 | 845 | 0.130 |
Why?
| | Parenting | 1 | 2021 | 319 | 0.130 |
Why?
| | Mentoring | 1 | 2020 | 165 | 0.130 |
Why?
| | Combined Modality Therapy | 2 | 2020 | 1266 | 0.130 |
Why?
| | Cluster Analysis | 2 | 2026 | 500 | 0.130 |
Why?
| | Human Growth Hormone | 1 | 2017 | 47 | 0.130 |
Why?
| | Carrier Proteins | 1 | 2021 | 728 | 0.130 |
Why?
| | Algorithms | 1 | 2024 | 1845 | 0.120 |
Why?
| | Pneumonia, Viral | 1 | 2022 | 389 | 0.120 |
Why?
| | Apolipoproteins | 1 | 2016 | 38 | 0.120 |
Why?
| | Memory | 1 | 2019 | 295 | 0.120 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2021 | 2158 | 0.120 |
Why?
| | Manganese Compounds | 1 | 2016 | 4 | 0.120 |
Why?
| | Fatty Acids, Unsaturated | 1 | 2016 | 96 | 0.120 |
Why?
| | Practice Guidelines as Topic | 1 | 2024 | 1581 | 0.120 |
Why?
| | Genetic Variation | 1 | 2021 | 972 | 0.120 |
Why?
| | Dextran Sulfate | 1 | 2016 | 93 | 0.120 |
Why?
| | Genomics | 1 | 2021 | 825 | 0.120 |
Why?
| | Verbal Learning | 1 | 2016 | 71 | 0.110 |
Why?
| | Influenza, Human | 1 | 2022 | 624 | 0.110 |
Why?
| | Outpatient Clinics, Hospital | 1 | 2016 | 80 | 0.110 |
Why?
| | Epilepsy | 1 | 2020 | 390 | 0.110 |
Why?
| | Logistic Models | 2 | 2020 | 2134 | 0.110 |
Why?
| | Pancreatic Neoplasms | 1 | 2024 | 928 | 0.110 |
Why?
| | Carotid Artery Diseases | 1 | 2015 | 70 | 0.110 |
Why?
| | Hyperlipoproteinemia Type III | 1 | 2015 | 4 | 0.110 |
Why?
| | Hyperlipoproteinemia Type I | 1 | 2015 | 7 | 0.110 |
Why?
| | Remission Induction | 1 | 2016 | 307 | 0.110 |
Why?
| | Colorado | 2 | 2015 | 4553 | 0.110 |
Why?
| | Attention | 1 | 2019 | 461 | 0.110 |
Why?
| | Chlorides | 1 | 2016 | 138 | 0.110 |
Why?
| | Ankle Brachial Index | 1 | 2015 | 41 | 0.110 |
Why?
| | Gene Deletion | 1 | 2016 | 391 | 0.110 |
Why?
| | Diet | 2 | 2020 | 1277 | 0.110 |
Why?
| | Phosphoproteins | 1 | 2017 | 337 | 0.110 |
Why?
| | Asymptomatic Diseases | 1 | 2015 | 104 | 0.110 |
Why?
| | Membrane Proteins | 1 | 2021 | 1164 | 0.110 |
Why?
| | Laser-Doppler Flowmetry | 1 | 2014 | 31 | 0.110 |
Why?
| | Heparin | 1 | 2016 | 247 | 0.100 |
Why?
| | Brain Concussion | 1 | 2022 | 644 | 0.100 |
Why?
| | Curriculum | 1 | 2021 | 1070 | 0.100 |
Why?
| | Forearm | 1 | 2014 | 141 | 0.100 |
Why?
| | Comorbidity | 3 | 2025 | 1661 | 0.100 |
Why?
| | Dietary Fiber | 1 | 2014 | 59 | 0.100 |
Why?
| | Vascular Remodeling | 1 | 2015 | 209 | 0.100 |
Why?
| | Memory, Short-Term | 1 | 2016 | 268 | 0.100 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2016 | 627 | 0.100 |
Why?
| | Nutrition Therapy | 1 | 2013 | 37 | 0.100 |
Why?
| | Exercise | 2 | 2022 | 2198 | 0.100 |
Why?
| | American Heart Association | 1 | 2014 | 358 | 0.090 |
Why?
| | Comparative Effectiveness Research | 1 | 2013 | 168 | 0.090 |
Why?
| | Analysis of Variance | 1 | 2015 | 1300 | 0.090 |
Why?
| | Fructose | 1 | 2013 | 132 | 0.090 |
Why?
| | Hospitals, Pediatric | 1 | 2016 | 558 | 0.090 |
Why?
| | Life Style | 3 | 2022 | 485 | 0.090 |
Why?
| | Regional Blood Flow | 1 | 2014 | 514 | 0.090 |
Why?
| | Hyperglycemia | 1 | 2016 | 379 | 0.090 |
Why?
| | Child, Preschool | 6 | 2026 | 11853 | 0.090 |
Why?
| | Glucose | 1 | 2017 | 1048 | 0.090 |
Why?
| | Quality Improvement | 1 | 2020 | 1295 | 0.090 |
Why?
| | Hot Temperature | 1 | 2014 | 396 | 0.090 |
Why?
| | Inservice Training | 1 | 2012 | 118 | 0.080 |
Why?
| | Observer Variation | 1 | 2012 | 357 | 0.080 |
Why?
| | Osteoarthritis | 1 | 2013 | 200 | 0.080 |
Why?
| | Polyethylene Glycols | 1 | 2016 | 649 | 0.080 |
Why?
| | Double-Blind Method | 2 | 2026 | 2062 | 0.080 |
Why?
| | Time Factors | 4 | 2020 | 7123 | 0.080 |
Why?
| | Adaptation, Psychological | 1 | 2016 | 716 | 0.080 |
Why?
| | Heart Ventricles | 1 | 2015 | 756 | 0.080 |
Why?
| | Femoral Artery | 1 | 2011 | 190 | 0.080 |
Why?
| | Mice, Inbred C57BL | 4 | 2025 | 5983 | 0.080 |
Why?
| | Tunica Media | 1 | 2009 | 37 | 0.080 |
Why?
| | Primary Health Care | 1 | 2020 | 1735 | 0.080 |
Why?
| | Tunica Intima | 1 | 2009 | 78 | 0.070 |
Why?
| | Skin | 1 | 2014 | 753 | 0.070 |
Why?
| | Feasibility Studies | 2 | 2025 | 1111 | 0.070 |
Why?
| | Glomerular Filtration Rate | 2 | 2023 | 765 | 0.070 |
Why?
| | Guideline Adherence | 1 | 2012 | 586 | 0.060 |
Why?
| | Research Design | 1 | 2013 | 1137 | 0.060 |
Why?
| | Drug Therapy, Combination | 2 | 2020 | 1044 | 0.060 |
Why?
| | Chromatography, Gel | 2 | 2017 | 130 | 0.060 |
Why?
| | Hemodynamics | 1 | 2012 | 1118 | 0.060 |
Why?
| | Mice, Knockout | 2 | 2025 | 3124 | 0.060 |
Why?
| | Peptide YY | 1 | 2026 | 28 | 0.060 |
Why?
| | Metformin | 2 | 2020 | 329 | 0.060 |
Why?
| | Resistin | 1 | 2025 | 12 | 0.060 |
Why?
| | Cameroon | 1 | 2025 | 8 | 0.060 |
Why?
| | Pregnancy Trimester, First | 1 | 2026 | 139 | 0.060 |
Why?
| | Africa South of the Sahara | 1 | 2025 | 54 | 0.060 |
Why?
| | Glucose Tolerance Test | 1 | 2026 | 360 | 0.050 |
Why?
| | Molecular Docking Simulation | 1 | 2025 | 119 | 0.050 |
Why?
| | Glucagon-Like Peptide 1 | 1 | 2026 | 149 | 0.050 |
Why?
| | Hepatocytes | 1 | 2025 | 224 | 0.050 |
Why?
| | South Africa | 1 | 2025 | 266 | 0.050 |
Why?
| | Polysomnography | 1 | 2025 | 239 | 0.050 |
Why?
| | Multicenter Studies as Topic | 1 | 2025 | 412 | 0.050 |
Why?
| | Reproducibility of Results | 1 | 2012 | 3413 | 0.050 |
Why?
| | Leptin | 1 | 2025 | 248 | 0.050 |
Why?
| | Goals | 1 | 2025 | 184 | 0.050 |
Why?
| | Inflammation | 1 | 2014 | 2878 | 0.050 |
Why?
| | Patient Education as Topic | 2 | 2020 | 777 | 0.040 |
Why?
| | Aged | 5 | 2021 | 26153 | 0.040 |
Why?
| | Family Characteristics | 1 | 2023 | 195 | 0.040 |
Why?
| | Body Composition | 1 | 2026 | 693 | 0.040 |
Why?
| | Binding Sites | 1 | 2025 | 1310 | 0.040 |
Why?
| | Mendelian Randomization Analysis | 1 | 2021 | 55 | 0.040 |
Why?
| | Diabetes Complications | 1 | 2023 | 224 | 0.040 |
Why?
| | Middle Aged | 5 | 2023 | 36215 | 0.040 |
Why?
| | Adipose Tissue | 1 | 2025 | 645 | 0.040 |
Why?
| | Infant | 3 | 2023 | 10077 | 0.040 |
Why?
| | Sitosterols | 1 | 2020 | 2 | 0.040 |
Why?
| | Protein Interaction Mapping | 1 | 2021 | 105 | 0.040 |
Why?
| | Minority Groups | 1 | 2023 | 284 | 0.040 |
Why?
| | Phytosterols | 1 | 2020 | 10 | 0.040 |
Why?
| | Phospholipids | 1 | 2022 | 214 | 0.040 |
Why?
| | Organ Dysfunction Scores | 1 | 2020 | 55 | 0.040 |
Why?
| | United Kingdom | 1 | 2021 | 344 | 0.040 |
Why?
| | Drug Discovery | 1 | 2021 | 153 | 0.040 |
Why?
| | Videoconferencing | 1 | 2020 | 65 | 0.040 |
Why?
| | Radiography | 1 | 2022 | 852 | 0.040 |
Why?
| | Schools | 1 | 2022 | 448 | 0.040 |
Why?
| | Anthropometry | 1 | 2019 | 206 | 0.040 |
Why?
| | Transition to Adult Care | 1 | 2020 | 103 | 0.040 |
Why?
| | Risk Reduction Behavior | 1 | 2020 | 217 | 0.030 |
Why?
| | Documentation | 1 | 2020 | 199 | 0.030 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2020 | 848 | 0.030 |
Why?
| | Safety | 1 | 2020 | 358 | 0.030 |
Why?
| | Molecular Targeted Therapy | 1 | 2021 | 439 | 0.030 |
Why?
| | Learning | 1 | 2022 | 443 | 0.030 |
Why?
| | Intensive Care Units, Pediatric | 1 | 2020 | 288 | 0.030 |
Why?
| | Diabetic Retinopathy | 1 | 2020 | 209 | 0.030 |
Why?
| | Inflammation Mediators | 1 | 2020 | 506 | 0.030 |
Why?
| | Focus Groups | 1 | 2020 | 569 | 0.030 |
Why?
| | RNA, Messenger | 1 | 2025 | 2803 | 0.030 |
Why?
| | Counseling | 1 | 2020 | 400 | 0.030 |
Why?
| | Self Efficacy | 1 | 2020 | 410 | 0.030 |
Why?
| | Liver | 1 | 2025 | 1896 | 0.030 |
Why?
| | Fasting | 1 | 2018 | 279 | 0.030 |
Why?
| | Students | 1 | 2022 | 651 | 0.030 |
Why?
| | Enzyme Activation | 1 | 2018 | 762 | 0.030 |
Why?
| | Ultrasonography | 1 | 2020 | 785 | 0.030 |
Why?
| | Apolipoproteins A | 1 | 2016 | 19 | 0.030 |
Why?
| | Mutation | 2 | 2018 | 4075 | 0.030 |
Why?
| | Gene Expression | 1 | 2021 | 1476 | 0.030 |
Why?
| | Healthy Volunteers | 1 | 2017 | 219 | 0.030 |
Why?
| | Disease Management | 1 | 2020 | 653 | 0.030 |
Why?
| | Pedigree | 1 | 2017 | 515 | 0.030 |
Why?
| | Societies, Medical | 1 | 2020 | 899 | 0.030 |
Why?
| | Self Report | 1 | 2020 | 870 | 0.030 |
Why?
| | Cell Line | 1 | 2021 | 2823 | 0.030 |
Why?
| | Autoimmunity | 1 | 2021 | 933 | 0.030 |
Why?
| | Nutrition Surveys | 1 | 2016 | 279 | 0.030 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2021 | 1140 | 0.030 |
Why?
| | Chi-Square Distribution | 1 | 2015 | 527 | 0.030 |
Why?
| | Spectrometry, Mass, Electrospray Ionization | 1 | 2015 | 174 | 0.030 |
Why?
| | Hospitals | 1 | 2019 | 732 | 0.030 |
Why?
| | Referral and Consultation | 1 | 2020 | 867 | 0.030 |
Why?
| | Body Weights and Measures | 1 | 2013 | 37 | 0.030 |
Why?
| | Models, Chemical | 1 | 2015 | 250 | 0.030 |
Why?
| | Pregnancy | 1 | 2026 | 7202 | 0.020 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2015 | 592 | 0.020 |
Why?
| | Fibrinogen | 1 | 2014 | 180 | 0.020 |
Why?
| | Parents | 1 | 2021 | 1403 | 0.020 |
Why?
| | Clinical Competence | 1 | 2020 | 1243 | 0.020 |
Why?
| | Sex Characteristics | 1 | 2017 | 782 | 0.020 |
Why?
| | Mental Disorders | 1 | 2020 | 1163 | 0.020 |
Why?
| | Registries | 1 | 2018 | 2406 | 0.020 |
Why?
| | Exercise Therapy | 1 | 2013 | 475 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2021 | 8333 | 0.020 |
Why?
| | Health Behavior | 1 | 2013 | 789 | 0.020 |
Why?
|
|
Shah's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|